Velocity of early BCR-ABL transcript elimination as an optimized predictor of outcome in chronic myeloid leukemia (CML) patients in chronic phase on treatment with imatinib

Leukemia

Volumn 28, Issue 10, 2014, Pages 1988-1992

  Hanfstein, B ^a   Shlyakhto, V ^a   Lauseker, M ^b   Hehlmann, R ^a   Saussele, S ^a   Dietz, C ^a   Erben, P ^a   Fabarius, A ^a   Proetel, U ^a   Schnittger, S ^c   Krause, S W ^d   Schubert, J ^e   Einsele, H ^f   Hanel M ^g   Dengler, J ^h   Falge, C ⁱ   Kanz, L ^j   Neubauer, A ^k   Kneba, M ^l   Stegelmann, F ^m   Pfreundschuh, M ⁿ   Waller, C F ^o   Spiekermann, K ^b   Baerlocher, G M ^p   Pfirrmann, M ^b   Hasford, J ^b   Hofmann, W K ^q   Hochhaus, A ^b   Muller M C ^a   more..

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

^c MLL MUNICH LEUKEMIA LABORATORY   (Germany)

^d UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^e EVANGELISCHES KRANKENHAUS   (Germany)

^f UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^g KLINIKUM CHEMNITZ   (Germany)

^h UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

ⁱ KLINIKUM NÜRNBERG   (Germany)

^j UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^k UNIVERSITY HOSPITAL MARBURG   (Germany)

^l UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^m UNIVERSITY HOSPITAL ULM   (Germany)

ⁿ SAARLAND UNIVERSITY   (Germany)

^o UNIVERSITY OF FREIBURG   (Germany)

^p UNIVERSITY OF BERN   (Switzerland)

^q JENA UNIVERSITY HOSPITAL   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BCR ABL PROTEIN; BETA GLUCURONIDASE; CYTARABINE; IMATINIB; ANTINEOPLASTIC AGENT; BENZAMIDE DERIVATIVE; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER PROGNOSIS; CANCER SURVIVAL; CHRONIC MYELOID LEUKEMIA; FEMALE; GENETIC TRANSCRIPTION; HAZARD RATIO; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; OVERALL SURVIVAL; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; VELOCITY; ADOLESCENT; CONTROLLED STUDY; DISEASE FREE SURVIVAL; GENETICS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; METABOLISM; MIDDLE AGED; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RANDOMIZED CONTROLLED TRIAL; RISK; SENSITIVITY AND SPECIFICITY; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BENZAMIDES; DISEASE-FREE SURVIVAL; FEMALE; FUSION PROTEINS, BCR-ABL; GLUCURONIDASE; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MIDDLE AGED; PIPERAZINES; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PYRIMIDINES; RISK; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84921801141     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2014.153     Document Type: Article

References (24)

1. Hehlmann R, Hochhaus A, Baccarani M, European L. Chronic myeloid leukaemia. Lancet 2007; 370: 342-350
2. Baccarani M, Cortes J, Pane F, Niederwieser D, Saglio G, Apperley J et al. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol 2009; 27: 6041-6051
3. Hanfstein B, Mü ller MC, Hehlmann R, Erben P, Lauseker M, Fabarius A et al. Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML). Leukemia 2012; 26: 2096-2102
4. Deininger M, O'Brien SG, Guilhot F, Goldman JM, Hochhaus A, Hughes TP et al. International randomized study of interferon vs STI571 (IRIS) 8-year follow up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib. ASH Annual Meeting Abstracts 2009; 114: 1126
5. Hochhaus A, Erben P, Ernst T, Mueller MC. Resistance to targeted therapy in chronic myelogenous leukemia. Semin Hematol 2007; 44(Suppl 1): S15-S24
6. Cortes J, Hochhaus A, Hughes T, Kantarjian H. Front-line and salvage therapies with tyrosine kinase inhibitors and other treatments in chronic myeloid leukemia. J Clin Oncol 2011; 29: 524-531
7. Saussele S, Lauseker M, Gratwohl A, Beelen DW, Bunjes D, Schwerdtfeger R et al. Allogeneic hematopoietic stem cell transplantation (allo SCT) for chronic myeloid leukemia in the imatinib era: evaluation of its impact within a subgroup of the randomized German CML Study IV. Blood 2010; 115: 1880-1885
8. Sokal JE, Cox EB, Baccarani M, Tura S, Gomez GA, Robertson JE et al. Prognostic discrimination in "good-risk" chronic granulocytic leukemia. Blood 1984; 63: 789-799
9. Hasford J, Pfirrmann M, Hehlmann R, Allan NC, Baccarani M, Kluin-Nelemans JC et al. A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group. J Natl Cancer Inst 1998; 90: 850-858
10. Hasford J, Baccarani M, Hoffmann V, Guilhot J, Saussele S, Rosti G et al. Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score. Blood 2011; 118: 686-692
11. Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood 2013; 122: 872-884
12. Marin D, Milojkovic D, Olavarria E, Khorashad JS, de Lavallade H, Reid AG et al. European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor. Blood 2008; 112: 4437-4444
13. Druker BJ, Guilhot F, O'Brien SG, Gathmann I, Kantarjian H, Gattermann N et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006; 355: 2408-2417
14. Hehlmann R, Lauseker M, Jung-Munkwitz S, Leitner A, Mü ller MC, Pletsch N et al. Tolerability-adapted imatinib 800 mg/d versus 400mg/d versus 400mg/d plus interferon-alpha in newly diagnosed chronic myeloid leukemia. J Clin Oncol 2011; 29: 1634-1642
15. Hughes TP, Hochhaus A, Branford S, Mü ller MC, Kaeda JS, Foroni L et al. Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS). Blood 2010; 116: 3758-3765
16. Marin D, Ibrahim AR, Lucas C, Gerrard G, Wang L, Szydlo RM et al. Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. J Clin Oncol 2012; 30: 232-238
17. Jabbour E, Kantarjian H, O'Brien S, Shan J, Quintas-Cardama A, Faderl S et al. The achievement of an early complete cytogenetic response is a major determinant for outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors. Blood 2011; 118: 4541-4546
18. Mü ller MC, Cross NC, Erben P, Schenk T, Hanfstein B, Ernst T et al. Harmonization of molecular monitoring of CML therapy in Europe. Leukemia 2009; 23: 1957-1963
19. Hughes T, Deininger M, Hochhaus A, Branford S, Radich J, Kaeda J et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood 2006; 108: 28-37
20. Emig M, Saussele S, Wittor H, Weisser A, Reiter A, Willer A et al. Accurate and rapid analysis of residual disease in patients with CML using specific fluorescent hybridization probes for real time quantitative RT-PCR. Leukemia 1999; 13: 1825-1832
21. Cross NC. Standardisation of molecular monitoring for chronic myeloid leukaemia. Best Pract Res Clin Haematol 2009; 22: 355-365
22. Anderson JR, Cain KC, Gelber RD. Analysis of survival by tumor response. J Clin Oncol 1983; 1: 710-719
23. Pfirrmann M, Hochhaus A, Lauseker M, Saussele S, Hehlmann R, Hasford J. Recommendations to meet statistical challenges arising from endpoints beyond overall survival in clinical trials on chronic myeloid leukemia. Leukemia 2011; 25: 1433-1438
24. Vigneri PG, Stagno F, Stella S, Cupri A, Forte S, Massimino M et al. High BCR-ABL levels at diagnosis are associated with unfavorable responses to imatinib mesylate. ASH Annual Meeting Abstracts 2012; 120: 2790.